Room For Innovative Switches Could Lurk In Existing FDA Framework
This article was originally published in The Tan Sheet
Executive Summary
When firms suggest submitting switch NDAs for “something that would be worth engaging on, we’re not going to tell you no,” says FDA nonprescription drug program chief Theresa Michele.
You may also be interested in...
Innovation In OTC Switches Takes Multimedia Approach In US FDA Draft Guidance
Sponsors can point consumers to video displays, website information and mobile apps to help them choose products that have been switched from Rx to OTC. Draft guidance on innovative switch applications to be followed by rule-making in near future.
Innovation In OTC Switches Takes Multimedia Approach In US FDA Draft Guidance
Sponsors can point consumers to video displays, website information and mobile apps to help them choose products that have been switched from Rx to OTC. Draft guidance on innovative switch applications to be followed by rule-making in near future.
OTC Switch Interest Cooled By Study Costs To Update Safety Data
Firms often are hesitant to prepare Rx-to-OTC switch applications because safety and efficacy data for their products are over a decade old, notes health care consultant Laura Mahecha.